Thyroid Cancer study: Iodine-124
Official title Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
ClinicalTrials.gov ID: NCT06961084
What this study is testing
What is Iodine-124?
This is an investigational radioactive iodine being studied to see if it can help find thyroid cancer that has spread. It is designed to be taken by mouth and travel to the thyroid area so a special camera can take pictures of it.
Also referred to as I-124.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if Iodine-124 PET/CT imaging is better at detecting metastatic thyroid cancer than the usual I-123 and I-131 scans.
- Who it's for
- This study is looking for people who have been diagnosed with thyroid cancer.
- What's involved
- Participants will receive an Iodine-124 injection and undergo a PET/CT scan. They will also have standard I-123 and I-131 scans for comparison.
- Time commitment
- The source text does not specify the total duration or the number of visits required.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 13 and older
You may be able to join if
- Age \>= 13 years.
- Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.
- American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.
- Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.
- Undergone total thyroidectomy.
You likely can't join if
- Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
- Known pregnancy.
See the full eligibility criteria
- Age \>= 13 years.
- Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.
- American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.
- Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.
- Undergone total thyroidectomy.
- Planned I-123 imaging within 45 days after enrollment.
- Ability to understand a written informed consent document, and the willingness to sign it.
- Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
- Known pregnancy.
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 13 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.